JPM 2024: Codagenix CEO Paul Grint on its COVID-19 and RSV Vaccine Development

2024-01-09

疫苗临床1期信使RNA临床结果

Pictured: A nasal vaccine being administered to a child/iStock, TopMicrobialStock 2023 was not a kind year for companies that invested heavily in the COVID-19 sphere, but Codagenix is still keeping on track with developing its vaccines for COVID-19 and other infectious diseases. Speaking to BioSpace in San Francisco, Codagenix CEO Paul Grint explained that the company, instead of going down the mRNA and single-antigen route, takes a live vaccine approach, using a “codon deoptimized live vaccine” to try to overcome the obstacles of live vaccines. Grint, who took over the CEO position in the summer of last year, said that while there have been cases of live vaccines working, they are not necessarily sophistical and can revert to the “normal wild type,” as seen with the oral polio vaccine. Grint said that Codagenix uses synthetic biology to change the codons in a viral genome, which “revs up” the replication process and essentially breaks the virus. Grint said the company initially targeted respiratory diseases such as influenza and RSV. When COVID-19 arose, Codagenix began developing a vaccine for the disease. “So we very quickly generated a COVID vaccine, did some small-scale Phase I studies, and showed intriguing data. But at the same time, what is critical because we’re a small company, I think we’re 27 people now. . . . But what’s been critical for us is we established a partnership with the Serum Institute of India,” Grint said. “And they liked our technology because, as part of developing the viruses, we’re able to grow these viruses in various cells, which are very commonly used for making all types of manufacturing, and it’s very productive.” In a Phase I trial the company said its nasal spray-based COVID-19 vaccine COVID-19 vaccine showed “robust induction of both humoral and cellular immune responses,” with T-cell reactivity that was specific for viral antigens. However, it is no secret that the broader biotech market has apparently soured on COVID-19 products, with Pfizer and Moderna seeing down quarters and reductions in sales around the disease. But Codagenix is still holding on and forging ahead with a vaccine. Grint said there is a $6 billion market for COVID-19 vaccines COVID-19 vaccines, and Codagenix secured a potential $389 million deal with BARDA in October of last year as well as working with the World Health Organization. Codagenix’s intranasal design provides a way to administer medicine fast and with “minimal side effects,” Grint said, making it easier to get into pediatric populations. And with Codagenix also in the hot RSV market, it will differentiate itself by having RSV programs for both adults and children, he added. “The first two, three, four years of life, [RSV is] a real problem and it’s . . . not just the general population, but I think significant parts of the medical community don’t appreciate how severe RSV outbreaks can be,” he said. “Yes, there’s work ongoing. Novartis has vaccines in development, but we believe that potentially, the pro again, an intranasal RSV vaccine for that younger population is an area of huge unmet medical need right now. So that’s where we’re focused.” Grint said that Codagenix hopes to have more data to release later this year. Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构